Table 2.
Profile of both groups at one year after liver transplantation.
| Variable | Normal kidney function at one year | Chronic kidney disease at one year | P Value |
|---|---|---|---|
| Group I (n = 380) | Group II (n = 33) | ||
| Age, years∗ | 51 (46-55) (24-63) | 49 (45.5-55) (43-63) | 0.642 |
| Gender male:female, n | 341:39 | 30:3 | 0.831 |
| Body mass index, kg/m2∗ | 28.4 (25.6-31.1) (17.6-43.74) | 27.9 (26.0-31.2) (21.3-34.63) | 0.807 |
| Serum creatinine before Tx∗ | 0.8 (0.6-1.0) (0.5-2.2) | 0.7 (0.6-0.9) (0.5-1.2) | 0.197 |
| Serum albumin before Tx, g/dl∗ | 2.9 (2.5-3.3) (1.5-5.5) | 2.7 (2.5-3.1) (1.5-3.9) | 0.237 |
| Serum total bilirubin before Tx, mg/dl∗ | 2.9 (1.8-4.3) (0.3-25) | 2.6 (1.65-4.35) (0.5-10.5) | 0.741 |
| INR before Tx∗ | 1.6 (1.3-1.9) (1-4.9) | 1.5 (1.35-2.1) (1.1-3.19) | 0.951 |
| MELD score before Tx∗ | 15 (13-18) (6-40) | 16 (12.5-20) (9-34) | 0.291 |
| GRWR∗ | 1.008 (0.9-1.2) (0.77-1.8) | 0.805 (0.8-0.9) (0.77-1.35) | < 0.0005 |
| Preoperative renal impairment, n (%) | 13 (3.42105) | 6 (18.18181) | < 0.0005 |
| HRS before Tx, n (%) | 12 (3.2) | 5 (15.2) | 0.001 |
| CI, minutes∗ | 35 (23-50) (10-175) | 35 (25.5-54.5) (16-120) | 0.349 |
| WI, minutes∗ | 44.5 (34-66.75) (18-175) | 49 (40-65) (31-95) | 0.306 |
| Hepatic vein anastomoses, n (%) | |||
| 1 | 258 (67.9) | 18 (54.5) | |
| 2 | 70 (18.4) | 10 (30.3) | 0.267 |
| 3 | 37 (9.7) | 5 (15.2) | |
| 4 | 14 (3.7) | 0 (0.0) | |
| 5 | 1 (0.3) | 0 (0.0) | |
| Portal vein anastomoses, n (%) | |||
| 1 | 372 (97.9) | 33 (100.0) | 0.400 |
| 2 | 8 (2.1) | 0 (0.0) | |
| Hepatic artery anastomoses, n (%) | |||
| 1 | 371 (97.6) | 33 (100.0) | 0.371 |
| 2 | 9 (2.4) | 0 (0.0) | |
| Intraoperative blood loss, ml∗ | 5400 (3700-7600) (550-16000) | 8500 (7000-9750) (1700-14000) | < 0.0005 |
| Fresh frozen plasma, n (%) | |||
| 0 | 235 (61.8) | 14 (42.4) | |
| 1-6 units | 48 (12.6) | 5 (15.2) | 0.072 |
| More than 6 units | 97 (25.5) | 14 (42.4) | |
| Operative time, minutes∗ | 575 (430-660) (300-960) | 800 (775-855) (400-940) | < 0.0005 |
| Immunosuppression in ICU | |||
| Tacrolimus | 244 (64.2) | 20 (60.6) | |
| Cyclosporin | 85 (22.4) | 8 (24.2) | 0.916 |
| Others | 51 (13.4) | 5 (15.2) | |
| AKI in ICU by creatinine criteria, n (%) | 119 (31.315789) | 9 (27.27272) | 0.630 |
| AKI in ICU by urine output criteria, n (%) | 44 (11.57894) | 5 (15.15151) | 0.543 |
| Biliary complications, n (%) | 28 (7.4) | 2 (6.1) | 0.781 |
| Acute rejection, n (%) | 37 (9.7) | 2 (6.1) | 0.488 |
| Hemodialysis, n (%) | 3 (0.8) | 0 (0) | 0.608 |
| Renal impairment at one month, n (%) | 70 (18.4) | 8 (24.2) | 0.412 |
| Survival, months∗ | 70 (45.25-96) (12-156) | 70 (52.5-98) (12-156) | 0.358 |
∗Data were expressed as median (interquartile range, IQR 25-75) (minimum-maximum) unless otherwise stated.
Statistically significant values are in bold.
Tx, transplantation; INR, international normalized ratio; MELD, model for end stage liver disease; GRWR, graft-to-recipient weight ratio; HRS, hepatorenal syndrome; CI, cold ischemia; WI, warm ischemia; ICU, intensive care unit; AKI, acute kidney injury.